Introduction
tumor, HGG, high-grade glioma, Malignant tumors, gliomas
TUMOR, SOLID TUMORS, MALIGNANT TUMOR, INFILTRATING, NEOVASCULARIZATION, GLIOMAS, TUMOR ANGIOGENESIS
Despite advances in treating recurrent high-grade glioma (HGG, WHO grade III and IV gliomas), the prognosis remains poor, and much work still needs to be done for improvement. Malignant tumors require neovascularization for growth, invasion, and metastasis[Tumor-associated macrophages (TAMs), defined as macrophages infiltrating the tumor microenvironment (TME), comprise 30–40% of the tumor mass in HGG and play a major role in promoting tumor angiogenesis and progression[SYHA1813 is a selective TKI that inhibits VEGFR-1 (half maximal inhibitory concentration [ICThe present study is a dose-escalation phase I clinical trial to evaluate the safety, pharmacokinetics (PK), maximum tolerated dose (MTD), efficacy, and potential biomarkers of SYHA1813 in patients with recurrent HGG or advanced solid tumors.